ZVIA vs. ASMB, TIL, VTVT, RLYB, PSNL, SLS, JAGX, CGTX, HOOK, and TKNO
Should you be buying Zevia PBC stock or one of its competitors? The main competitors of Zevia PBC include Assembly Biosciences (ASMB), Instil Bio (TIL), vTv Therapeutics (VTVT), Rallybio (RLYB), Personalis (PSNL), SELLAS Life Sciences Group (SLS), Jaguar Health (JAGX), Cognition Therapeutics (CGTX), Hookipa Pharma (HOOK), and Alpha Teknova (TKNO). These companies are all part of the "medical" sector.
Assembly Biosciences (NASDAQ:ASMB) and Zevia PBC (NYSE:ZVIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
In the previous week, Zevia PBC had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Zevia PBC and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.42 beat Zevia PBC's score of 0.04 indicating that Zevia PBC is being referred to more favorably in the news media.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 53.2% of Zevia PBC shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by insiders. Comparatively, 12.6% of Zevia PBC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -15.58%. Assembly Biosciences' return on equity of -37.98% beat Zevia PBC's return on equity.
Zevia PBC has a consensus price target of $3.21, suggesting a potential upside of 239.40%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Zevia PBC is more favorable than Assembly Biosciences.
Assembly Biosciences received 227 more outperform votes than Zevia PBC when rated by MarketBeat users. Likewise, 59.31% of users gave Assembly Biosciences an outperform vote while only 31.91% of users gave Zevia PBC an outperform vote.
Assembly Biosciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Zevia PBC has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Zevia PBC has higher revenue and earnings than Assembly Biosciences.
Summary
Zevia PBC beats Assembly Biosciences on 12 of the 16 factors compared between the two stocks.
Get Zevia PBC News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevia PBC Competitors List
Related Companies and Tools
